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Abstract
Aim: To develop and evaluate the comparative effectiveness of behavioural interventions of
enhanced prevention counselling (EPC) and simple educational counselling (SEC) in reducing
hepatitis C viral (HCV) infection in sero-negative injecting drug users (IDU).
Design:  Randomised controlled trial (RCT) of EPC intervention in comparison with simple
educational counselling (SEC).
Setting Specialised: Drug services in London and Surrey, United Kingdom.
Participants and Measurements: Ninety five IDUs were recruited and randomised to receive
EPC (n = 43) or SEC (n = 52). Subjects were assessed at baseline using the Addiction Severity Index
(ASI), the Injecting Risk Questionnaire (IRQ), and Drug Injecting Confidence Questionnaire
(DICQ). The primary outcome was measured by the rate of sero-conversion at 6 months and 12
months from baseline and by the ASI, IRQ and DICQ at 6 months from baseline. Hepatitis C testing
was undertaken by the innovative test of the dried blood spot (DBS) test which increased the rate
of testing by 4 fold compared to routine blood testing.
Findings Seventy: Eighty two subjects (82%) out of the 95 recruited were followed up at 6
months and 62 (65%) were followed up at 12 months. On the primary outcome measure of the
rate of seroconversion, 8 out of 62 patients followed-up at twelve months seroconverted, three in
the EPC group and five in the SEC group, indicating incidence rates of 9.1 per 100 person years for
the EPC group, 17.2 per 100 person years for the SEC group, and 12.9 per 100 person years for
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the cohort as a whole. Analysis of the secondary outcome measures on alcohol use, risk behaviour,
psychological measures, quality of life, showed no significant differences between the EPC and the
SEC groups. However, there were significant changes on a number of measures from baseline
values indicating positive change for both groups.
Conclusion: We were not able to prove the efficacy of EPC in comparison with SEC in the
prevention of hepatitis C in IDUs. This was related to low recruitment and retention rates of the
participants. Moreover there was a low adherence rate to EPC. The study provided the benefits of
developing and introducing behavioural interventions of the EPC and SEC and the DBS screening
for Hepatitis C. Moreover the main lessons learnt were that piloting of a new intervention is a
crucial first step before conducting pragmatic RCTs of psychological interventions in the field of
addiction; that an infrastructure and culture for psychosocial interventions is needed to enable
applied research in the service environment, and research funding is needed for enabling the
recruitment of dedicated trained therapists for the delivery of these interventions.
Background
Viral hepatitis C is a global public health problem, and
has been considered one of the major challenges in the
third millennium [1]. Injecting drug use is the main route
of transmission, mediated by the sharing of injection
equipment, especially needles and syringes but also
spoons, cotton filters and other paraphernalia [2]. In the
UK, studies of prevalence rates of anti-HCV amongst
Injecting Drug Users (IDUs) reported rates of 80%–86%
in England (5 studies) and 37%–90% in Scotland (3 stud-
ies) [3]. The association between injecting drug use and
infection with HCV is mediated by sharing needles and
syringes or other injecting paraphernalia. European stud-
ies showed rates of sharing needles and syringes and other
injecting paraphernalia between 70% and 94% [4].
The recently introduced Hepatitis C Strategy for England
[5] laid strong emphasis on preventing new cases of hep-
atitis C infection in IDUs by health promotion activities
and the provision of needle exchange schemes. This is best
achieved in the context of treatment for drug dependence
complemented with information about hepatitis C and
harm minimisation messages. However, this new policy
falls short of recommending specific preventive interven-
tions which are evidence based; hence the importance of
this project which aims to evaluate a new preventive inter-
vention for hepatitis C in IDU's.
The aim of the present study was to evaluate the effective-
ness of enhanced prevention counselling (EPC) in reduc-
ing HCV infection in HCV sero-negative patients. Our
primary hypothesis was that EPC is more effective and
cost-effective than simple educational counselling (SEC)
in reducing the rate of HCV sero-conversion and its risk
behaviour. Whilst we have also evaluated sexual risk
behaviour in relation to the occurrence of HCV, we have
not studied the prevalence and seroconversion rates of
hepatitis B, HIV and other sexually transmitted diseases.
However we were not able to prove the efficacy of EPC in
comparison with SEC in the prevention of hepatitis C in
IDUs. This was related to low recruitment and retention
rates of the participants. Moreover there was a low adher-
ence rate to EPC.
In view of these reported negative findings, we have also
provided an overview of the main problems that we faced
and our attempts to overcome them, in the hope that it
will guide future researchers in the field of prevention
interventions in addiction [6].
Methods
The study was conducted in 2 phases, a screening phase
and an intervention phase.
Screening phase
Injecting drug users presenting to collaborating drug treat-
ment services in South West London, North London and
in Surrey were screened for eligibility in four steps: (1) the
identification of IDUs, (2) distinguishing between those
IDUs that have injected at least once in the last six months
and those that have not, (3) assessment of IDUs for inclu-
sion and exclusion criteria and (4) eligibility by testing for
current HCV sero-positivity using a standard ELISA HCV
antibody test [7]. All IDUs who were confirmed to be HCV
sero-negative by HCV antibody test were invited to attend
a research interview conducted by the research workers.
This occurred in the context of their ongoing care. Succes-
sive IDUs referred to community drug services were
recruited to the trial as well those who were in treatment.
The overall retention in treatment rate during the trial was
60% with no difference in retention rates between those
receiving EPC and SEC.
Inclusion Criteria were
(1) male and female IDUs (2) age 18–70 years (3) ICD-10
diagnosis of mental and behavioural disorder due to theHarm Reduction Journal 2008, 5:25 http://www.harmreductionjournal.com/content/5/1/25
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use of drugs (F11-F19) established by baseline research
interview (4) willingness to nominate an independent
informant to provide collateral information, and nomi-
nate a locator who can assist in tracing the subject at fol-
low-up (5) stable place of residence (defined as having a
domicile for which there is no imminent danger of evic-
tion) and (6) living close enough to commute to the
clinic.
Exclusion Criteria were
(1) current severe mental illness (e.g. bipolar effective dis-
order or schizophrenia), (2) severe physical illness that
would preclude participation, (3) serious legal problems,
including impending imprisonment, likely to interfere
with treatment participation and/or follow-up and (4)
severe brain damage or mental impairment. The inclusion
and exclusion criteria were established by a combination
of clinical assessment by service staff, and baseline
research interview conducted by the research workers.
Ethical approval for the research was sought and obtained
from both the Multi-Centre Research Ethics Committee
(MREC) and relevant Local Research Ethics Committees
(LREC) where recruitment took place. The recruitment
process, issues of information provision, consent, confi-
dentiality, data protection, management of the research,
and all other aspects of the Trial were modelled on the rec-
ommendations for good research and clinical practice
provided by the MREC and LREC guidelines.
Baseline assessment
All drug users were assessed using the European Addiction
Severity Index [8], Injecting Risk Questionnaire (IRQ) [9],
the HIV Risk Taking Behaviour Scale [10] and Alcohol Use
Disorders Identification Test (AUDIT) Questionnaire
[11]. Self-efficacy, outcome expectancies (situational con-
fidence) were measured using an adapted version of the
Situational Confidence Questionnaire [12]. Finally, stages
of change in the "readiness to change" model [13] were
assessed using the Readiness to Change questionnaire,
and general knowledge on hepatitis C measured using a
custom-designed questionnaire.
Intervention phase
After the completion of a baseline assessment, all clients
were randomised to receive either the Enhanced Preven-
tion Counselling (EPC) or Simple Educational Counsel-
ling (SEC) intervention. The therapists who administered
the interventions were regular staff of community drug
services that took part in the trial. All therapists received
an intensive training programme in the administration of
manualized EPC and SEC from PD who is an accredited
clinical psychologist with national expertise in training
clinicians in psychological interventions. The therapists
received regular supervision from PD and other trained
supervisors who completed the intensive training in EPC
intervention and the techniques of supervision from PD.
For quality control, all sessions were audio-taped to meas-
ure the fidelity of the EPC and SEC interventions.
Enhanced prevention counselling
This comprised four sessions of manual-guided interven-
tion. The manual was based on a number of other treat-
ment intervention manuals, and particularly on the Brief
Intervention (Motivational Enhancement Therapy) used
in Project Match (Project MATCH Research Group, 1998),
and the manual established and evaluated for project
RESPECT which was concerned with the reduction of
high-risk sexual behaviour and the introduction of safer
sex [14]. In addition, exercises and elements were taken
from substance misuse cognitive behavioural treatments
[15], and elaborated in therapy manuals [16,17].
The four sessions were intended to be completed within
eight weeks of entry into the programme and were carried
out by a drug clinic worker who was trained in delivering
the intervention but who was not involved in collecting
outcome data from participants. The aim of the interven-
tion was to reduce risk behaviours associated with the
acquisition of HCV infection in injecting drug users. HCV
transmission risk behaviours include injecting drugs, the
sharing of injecting equipment, not cleaning and reusing
drug paraphernalia, alcohol misuse, cocaine use, unpro-
tected sexual activity, multiple sexual partners, and non-
compliance with methadone treatment.
EPC as applied in this project utilises principles of moti-
vational psychology, theories of behaviour change (partic-
ularly social cognitive learning theory), and health belief
models, including the theory of reasoned action [18,19].
Changes in risk behaviour are hypothesised to take place
through changes in outcome expectancies (expected con-
sequences of a course of action, e.g. sharing injecting
equipment) and self efficacy (confidence in one's ability
to achieve a particular goal, e.g. avoidance of sharing
injecting equipment). Motivational interventions have
been applied to a variety of health behaviours in addition
to addictive behaviour (reviewed in Miller and Rollnick
[20]; [21], and can be readily applied to health promotion
in drug misusers. The aim of the intervention is to
enhance the subject's self-perception of risk and facilitate
the development of individual strategies to avoid engag-
ing in HCV risk activities. The measurement of self-effi-
cacy will allow assessment of the process of the
intervention.
All sessions last between 40–60 minutes and follow the
format of the brief interventions described above. Session
one has the aim of establishing rapport and a counselling
relationship consistent with the principles of Motiva-Harm Reduction Journal 2008, 5:25 http://www.harmreductionjournal.com/content/5/1/25
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tional Interviewing, increasing knowledge and awareness
of HCV risk behaviours and the consequences of HCV
infection, introducing the rationale and structure of the
intervention to the subject, and assessing the individual's
risk behaviours, self efficacy and outcome expectancies.
The remaining three sessions begin with a review of
progress on targets set at the previous session, assessment
of any difficulties in applying coping strategies, and
assessment of the subject's motivational state. In the sec-
ond session, if appropriate, targets for intervention are
planned (e.g. unprotected sexual activity, injecting equip-
ment sharing). Each session ends with a behavioural goal-
setting exercise in which the participant arrives at a small
behavioural risk-reduction step that could be achieved by
the next session. At the end of the final session, a longer-
term, individualised risk reduction plan is agreed upon.
Various strategies are employed in EPC to foster compli-
ance with the intervention, including the development of
a therapeutic alliance, individual risk reduction plans to
take home as a reminder of behavioural goals, appoint-
ment cards, combining sessions with regular clinic visits
(e.g. for methadone prescriptions), and phoning the sub-
ject on the day of visits as a reminder.
Simple Educational Counselling (SEC)
This consisted of a ten-minute session of information-giv-
ing intervention about the nature and the risk factors of
HCV, with advice on prevention including the need to
reduce sharing of injecting equipment and safer injecting
practices. It was intended to be a non-interactive interven-
tion in order to contrast with the EPC, and clients were
asked to direct any questions they might have to their key
worker rather than the counsellor.
Outcome Measurement
Research follow up interviews were conducted at six
months post randomisation, and blood tests for hepatitis
C at both six months and twelve months. The primary
outcome measure was the number of new cases of HCV
infection by sero-conversion detected by HCV positive
antibody at 6 and 12 months from recruitment. Second-
ary outcome measures were those administered at base-
line.
Sample size
Power calculations were based upon rates of sero-conver-
sion of 6% per hundred person years found in a research
study that applied intensive preventative counselling to
IDUs [22]. This was compared with the rate of sero-con-
version obtained from research into the IDU population
of 20% per hundred person years [23]. Based on these fig-
ures, the difference was estimated to be around 14%, and
so with a power of 0.8 and a difference proven at the 5%
level using a two-tailed test, a followed-up sample of 180
IDUs was required.
Randomisation
Randomisation was stratified by two variables in order to
provide a control for what were perceived to be poten-
tially important influences. The stratification variables
were the "Treatment Centre" that the client was recruited
from, to control for differences in standard service at each
of the recruitment sites, and "Injecting Equipment Shar-
ing Behaviour", to control for a very important risk-factor
predictor for contracting hepatitis C. Stratification was
achieved in blocks of six within each variable, such that in
each block of six half of the clients would receive SEC and
half of the clients EPC. This method of stratified randomi-
sation was chosen over true randomisation in order to
ensure that allocation to either group was fairly constant
throughout the life of the trial, helping to maximise ther-
apist time by spreading the workload more evenly. It was
also intended to act as a safeguard against bias to one
intervention or the other if lower than expected levels of
recruitment were achieved.
The physical implementation of the randomisation
scheme was accomplished by a custom-designed statisti-
cal computer program which generated stratified random
integers between 1 and 2 in blocks of six; these were then
transcribed onto cards and sealed in envelopes by a per-
son unconnected with the Research Team, so that they
never had any access to the randomisation scheme used.
Envelopes were marked sequentially on the outside, and
were opened by the Research Team upon completion of a
baseline interview. Other features which contributed to
the protection of the validity of the Trial and maximising
the quality of the data included the written protocol that
was followed, the manual-guided treatment interven-
tions, and quality control of the interventions through the
rating and assessing of a random sample of tapes from the
sessions.
Blinding
Although it would have been preferable for the purposes
of completely eliminating the potential for bias to make
the Research Team blind to the therapy intervention allo-
cated, due to the Research Team's need to co-ordinate and
help facilitate the implementation of the intervention this
was not possible. Once the therapy allocation was made,
the Research Team had to locate a suitable therapist to
conduct the intervention and liaise with them over the
progress that they were making with the clients allocated
to them, and this applied to both EPC and SEC therapists.
Arrangements for the payment of travel expenses for cli-
ents attending the EPC sessions also had to be made
(sometimes for both client and therapist), and the
researchers also played a large role in chasing up clients
who did not attend their sessions. Thus, although it may
have been possible to implement a blinding procedure, it
was felt that the benefits of doing so were outweighed byHarm Reduction Journal 2008, 5:25 http://www.harmreductionjournal.com/content/5/1/25
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the increases in efficiency gained otherwise. It was also felt
that not blinding would have minimal impact on the
research outcomes as the primary outcome measure was
rate of sero-conversion, which is not open to bias, and in
addition majority of the interview measures were direct
and quantitative rather than subjective and qualitative.
Statistical Analyses
Data analysis was conducted on intention to treat basis.
The primary hypothesis was tested using chi-square for
comparison of rates of sero-conversion and using analysis
of covariance with risk-behaviour composite scores as
dependent variables, controlling for baseline values on
these measures, and treatment condition as the independ-
ent variable. Similar analysis was carried out on secondary
outcome measures with calculations of differences
between intervention groups and differences between the
group who were and the group who were not followed up.
Incidence of HCV was calculated using the person years
method [24] among IDUs who were sero-negative for
HCV antibody and who had repeated testing after 6 and
12 months from baseline testing. Analyses of covariance
were performed for all relevant secondary outcome meas-
ures, using baseline scores as the first covariate to control
for initial individual differences, and baseline score on the
injecting subscale of the HIV Risk-Taking Behaviour Scale
as the second covariate where appropriate, as this subscale
was identified as being significantly different between the
two interventions. Chi-square analyses were performed
for all categorical data and Mann-Whitney U-Tests for
ordinal data that were not normally distributed to apply
parametric tests.
Dried Blood Spot (DBS) testing for hepatitis C
When recruitment began, it was found that far less testing
of hepatitis C was happening at community drug teams
than was reported, and this proved to be a major obstacle
for the trial. It was suggested this could be overcome with
the implementation of the Dried Blood Spot (DBS) test
[25] for hepatitis C, and after seeking approval from the
Department of Health and the Trial Steering Committee
the procedure was adopted at all recruitment centres. A
study into the validity of the DBS test revealed it to have
100% sensitivity and 100% specificity [26], and our own
piloting work confirmed this. The introduction of the DBS
test increased testing more than fourfold, greatly assisting
the recruitment process.
Results
Baseline analysis
Participants
A flow diagram detailing the number of IDUs at each stage
of the recruitment process is presented in figure 1. As
shown 95 subjects were recruited and 78 were followed
up at 6 months and 62 were followed up at 12 months.
Demographic characteristics
The mean age of all those recruited was 32 years (SD 6.7).
There were 70 males, 25 females, 10% were married, 42%
had at least one child, 43% were unemployed and 48%
had educational qualifications. There were no significant
differences on these basic demographic characteristics
between both those followed-up and those not followed-
up and between those allocated to EPC and those allo-
cated to SEC.
Drug use and other characteristics
Participants showed the following drug use characteristics
(means and SDs): duration of drug use (11.4, 7.6 years),
age of first drug injection (24.5, 6.3 years), duration of
injecting drug use (5.9, 4.8 years), previous episodes of
treatment (3.1, 2.9) and inpatient treatment episodes
(1.8, 3.1). Every recruited client was currently receiving a
prescription for a substitute drug with methadone being
the most commonly reported drug at 85%, with the
remainder prescribed buprenorphine. One of the main
criteria for recruitment was having injected at least once in
the past six months, but 49% of respondents reported
having injected in the last thirty days. The vast majority
were regular smokers of cigarettes (89%), and 70% drank
alcohol at least once per week, 35% reported that a mem-
ber of their immediate family had a history of alcohol
problems, 31% reported a family history of drug prob-
lems, and 28% reported a family history of psychiatric
problems, 41% reported a history of emotional abuse by
significant others, 23% reported a history of physical
abuse, and 11% reported incidences of sexual abuse.
There were no significant differences between those fol-
lowed-up and those not followed-up, or between those
allocated to either intervention, on any of these measures.
Standardised measures
On the ASI just under 56% of clients had shared an item
of injecting equipment in the last six months, with the
mean number of people that they had shared with being
1.84 for the subgroup of those who admitted to any shar-
ing at all, or 1.08 overall. Scores on the HIV Risk-Taking
Behaviour Scale were expectedly high, particularly for
injecting risk (mean 8.8, SD 5.7) as opposed to sexual risk
(mean 4, SD 4.1), 37% were identified as having a proba-
ble drink problem by the AUDIT and 54% had used a nee-
dle exchange at least once in the last six months.
The only significant differences on all measures between
those followed-up and those not followed-up were on the
legal and economic subscales of the ASI, with those not
followed up exhibiting relatively higher degrees of prob-
lem on both measures than those followed-up. There was
one significant difference between the intervention
groups, with those allocated to EPC scoring more highlyHarm Reduction Journal 2008, 5:25 http://www.harmreductionjournal.com/content/5/1/25
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Number of participants at each stage of the recruitment process Figure 1
Number of participants at each stage of the recruitment process.
Assessed for Eligibility 
1354 IDUs
(injected drugs at some point 
in their lives) 
referred to trial recruitment 
Ineligible II (46%)   
329 – Not injected in last 6 months 
245 – Not known if injected in last 6 months 
10 – Mental health exclusions 
12 – Under age 18
Eligible for HCV blood test 
according to first criteria 
758  (56%)
Ineligible III (62%) 
237 – tested HCV positive in the past 
14   – refused HCV blood test 
216 – not tested
Tested for HCV 
291 (38%) 
(240 DBS, 51 venous samples)
Ineligible IV (29%) 
85 – HCV positive
Seronegative IDUs 
206 (71%)
Randomised 
95 (46%)
Drop-out/Refused (54%) 
44 – not engaged with service any more 
67 – refused
6 month 
follow up
41 (79%)
6 month 
follow up
37 (86%)
Lost to follow-up (18%) 
17 - follow-ups overdue
SEC
52 (55%)
EPC
43 (45%)
12 month 
blood test
33 (77% of 
recruited)
12 month 
blood test
29 (56% of 
recruited)
Client presents at 
recruitment centre 
Ineligible I   
Never injected – number not specifiedHarm Reduction Journal 2008, 5:25 http://www.harmreductionjournal.com/content/5/1/25
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on the injecting subscale of the HIV Risk-Taking Behav-
iour Scale, although not scoring significantly differently
overall. As this subscale is quite important, indicating a
higher level of sharing behaviour that could have an
impact on the outcome variables and the trial interven-
tion, this measure was used as a covariate where appropri-
ate in the outcome analysis.
Psychological Measures
Confidence at resisting the urge to inject, measured by the
Drug Injecting Confidence Questionnaire, was on average
59%, but large variations were noted across subjects.
Unpleasant emotions, urges and temptations, and social
pressure to use were areas where respondents were least
likely to resist the urge to inject, whilst circumstances of
pleasant emotions was the area where patients were most
confident that they would not inject. Knowledge of hepa-
titis C, as measured by our item true-or-false question-
naire was better than expected, with average scores of over
16 out of twenty. "Stage of change", measured by the
Readiness to Change Questionnaire, revealed that the
majority of subjects were at the "Action" stage of change,
probably reflecting the locations from which they were
recruited. There were no significant differences on these
measures between those followed-up and those not fol-
lowed-up, or between those allocated to either of the trial
interventions.
Outcome analysis
As shown in Figure 1, out of 95 participants recruited, 78
(82%) were followed up at 6 months and 62 (65%) were
followed up at 12 months. These follow up rates do not
correspond to retention rates in treatment as some of the
participants had dropped out from treatment but agreed
to attend for the follow-up research interview and HCV
testing. Moreover for SEC, 41 (79%) attended at 6 months
and 29 (56%) at 12 months whilst for EPC, 37 (86%)
attended at 6 months and 33 (77%) at 12 months.
Table 1 illustrates the number of participants who
engaged for their allocated intervention, defined as either
completing the SEC intervention or attending for at least
one session of EPC of those followed-up. Table 2 illus-
trates the number of completed sessions of EPC.
There was a significant difference between the two groups
in terms of their engagement with the therapy interven-
tion (p < 0.000). 78 participants were followed-up at six
months (82.1%), and 62 at 12 months (65.3%). Overall,
six-month follow-up data indicated a seroconversion rate
of 9.0% in six months, or 18.0% per year. Twelve-month
follow-up data indicated a seroconversion rate of 12.9%
per year.
The difference in seroconversion was not significant
between the two interventions at either six months or
twelve months, but it was however in the anticipated
direction, with fewer of those allocated to EPC serocon-
verting compared to those that received SEC. The differ-
ence was even more pronounced (but still not significant)
when only those who received at least one session of the
intervention were included as no patients who received at
least one session of EPC seroconverted at either six
months or twelve months.
There were no significant differences between the EPC and
SEC groups on any of the secondary outcome measures
(effect of treatment). However there were significant
changes in a number of measures for both groups at 6
months follow-up (effects of time). Table 3 shows signifi-
cant changes for ASI alcohol use, medical subscale, eco-
nomic subscale, satisfaction subscale and HIV-RTBS
injecting risk, sexual risk behaviour and overall scores.
Table 4 shows non significant reduction in injecting
behaviour, sharing, use of needle exchange and AUDIT in
the last 6 months.
Table 5 shows significant changes in all DICQ scales indi-
cating moderate increases in situational confidence in the
ability to resist the urge to inject and increases in Hepatitis
C knowledge questionnaire.
Table 1: Participants engaged, not engaged, sero converted and incidence of HCV in EPC and SEC groups
Number
 Engageda
Number
 Not engaged
Number
Sero
  converted
Total Incidence of HCV 
 (per 100 person years)
EPC 17* (45.9%) 20 (54.1%) 3 b 37 9.1
SEC 38 (92.7%) 3 (7.3%) 5 c 41 17.2
Total 55 (70.5%) 23 (29.5%) 8 78 12.9
* Chi-squared test χ2 = 20.43, p < 0.000
(EPC) Enhanced Prevention Counselling
(SEC)Simple Education Counselling
a Number of participants completing EPC sessions: none 20; one session 6; two sessions 4; three sessions none and four sessions 7.
b Three participants seroconverted at 12 months: none engaged with EPC: HCV incidence 9.1 per100 person years
c Five particpants seroconverted at 12 months: 4 engaged with SEC: HCV incidence 17.2 per 100 person yearsHarm Reduction Journal 2008, 5:25 http://www.harmreductionjournal.com/content/5/1/25
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Scores on the HIV Risk-Taking Behaviour Scale similarly
reduced for both groups, with the EPC group in particular
exhibiting a large reduction in injecting behaviour which
put them at a similar level to the SEC group, eradicating
the difference that was present at baseline. Baseline scores
on the HIV Risk-Taking Behaviour Scale did not account
for differences on any of the outcome measures.
Discussion
We were not able to demonstrate the efficacy of EPC com-
pared to SEC in the prevention of hepatitis C amongst
injecting drug users. The main reasons for this were the
lower than expected levels of recruitment, coupled with
the lower than expected compliance with the experimen-
tal intervention. The EPC and SEC groups were well
matched in their demographic characteristics, drug use
and psychological characteristics, including measures of
risk behaviour. Levels of injecting equipment sharing
behaviour were similar to that reported in other studies,
with around 60% of all users who had injected in the past
six months reporting sharing behaviour over the same
period [5]. Of note is the difference in follow-up rates of
SEC (56%) and EPC (77%) groups at 12 months. It is not
certain whether this difference in follow up rate had any
effect on the trial's internal validity and we have no expla-
nation for this finding. Moreover these follow up rates do
not correspond to retention rates in treatment as some of
the participants had dropped out from treatment but
agreed to attend for the follow-up research interview and
HCV testing.
The difference in seroconversion was not significant
between the two interventions at either six months or
twelve months, but it was however in the anticipated
direction, with fewer of those allocated to EPC serocon-
verting compared to those who received SEC. The differ-
ence was even more pronounced (but still not significant)
when only those who received at least one session of the
intervention were included as no patients who received at
least one session of EPC seroconverted at either six
months or twelve months. However, given the relatively
low numbers of participants recruited and followed-up,
and the differential rate of engagement in EPC and SEC
and the even lower number of those who completed all 4
sessions of EPC therapy, no conclusions could be drawn
and the efficacy of EPC in reducing new cases of HCV
remains inconclusive.
Notably, there were many significant changes on some of
the secondary outcome measures from baseline values,
indicating positive change and improvement for both
groups. These reductions in drug use and risk behaviour
may reflect the impact of their treatment in general rather
than any specific effects of the interventions. The finding
Table 2: Number of participants who completed or have not 
completed EPS and the number of sessions completed
Number of
 EPC Sessions
None One Two Three Four
(course
  completed)
Number of
participants
20 6 4 0 7
Table 3: Changes in addiction severity and risk behaviour
Drug and Alcohol Baseline Six-Month follow-up
EPC n = 37 SEC n = 41 EPC n = 36 SEC n = 41 Effect of 
Treatment
Effect of
 Time
ANCOVA Mean sd Mean sd Mean sd Mean sd F p F p
ASI – drug use 0.286 0.12 0.29 0.096 0.22 0.152 0.249 0.133 0.90 0.35 0.54 0.47
ASI – alcohol use 0.084 0.17 0.115 0.176 0.113 0.176 0.082 0.143 2.26 0.14 41.08 0.00
ASI – medical subscale 0.138 0.26 0.134 0.278 0.092 0.207 0.156 0.294 0.95 0.33 10.97 0.00
ASI – psychiatric subscale 0.208 0.26 0.174 0.204 0.204 0.241 0.159 0.207 0.34 0.56 3.74 0.06
ASI – Legal subscale 0.094 0.16 0.119 0.182 0.093 0.151 0.09 0.177 0.01 0.92 0.80 0.38
ASI – economic subscale 0.877 0.32 0.652 0.432 0.765 0.357 0.766 0.381 0.83 0.67 8.56 0.01
ASI – satisfaction subscale 0.289 0.31 0.235 0.27 0.222 0.334 0.154 0.266 0.65 0.42 5.72 0.02
ASI – family relationships 0.101 0.16 0.13 0.209 0.075 0.133 0.077 0.151 0.02 0.89 2.31 0.13
ASI – social relationships 0.104 0.19 0.085 0.133 0.03 0.102 0.039 0.084 0.13 0.72 2.07 0.16
IRQ – No. people shared IV
equipment with in last 6
months
0.81 0.88 1.32 1.4 0.22 0.64 0.37 0.97 1.1 0.31 0.00 0.98
HIV RTBS – Drug score 9.95 5.74 8.02 5.8 3.31 5.3 3.4 5.6 0.4 0.55 10.0 0.00
HIV RTBS – Sex score 4.5 4.2 3.1 3.4 4.7 4.2 3.9 4.14 0.1 0.78 8.2 0.01
HIV RTBS – Overall 13.8 7.45 11.2 6.98 8.0 8.12 7.3 6.86 0.0 0.84 11.4 0.00Harm Reduction Journal 2008, 5:25 http://www.harmreductionjournal.com/content/5/1/25
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that only half of the initial sample had injected in the last
month at baseline, would suggest a broad treatment effect
i.e. injecting behaviour had already stopped in half of the
participants at intake. A recently reported RCT of a brief
behavioural intervention in comparison with standard-
ised educational intervention for reducing HCV risk prac-
tices among IDUs showed a reduction in these practices
for both interventions at one month follow-up [27]. The
study failed to demonstrate effectiveness of the brief inter-
vention for a number of reasons: similarity between the
interventions in duration and content, the short follow-
up of one month and the inclusion of HCV positive IDUs.
It was also worthy of note that 60% of this high-risk group
had never been tested for HCV prior to this research,
despite the cohort being engaged at local community drug
teams. In addition, 10% of those who had been tested in
the past, and who believed themselves to be HCV sero-
negative, were found to be HCV sero-positive, emphasis-
ing the need for regular testing of IDUs.
Possible reasons for the low overall incidence of 12.9 per
100 person years are the impact of treatment on risk
behaviour [28], HCV screening and the provision of harm
reduction approaches in the community. However there
has been the notion that the impact of needle exchange
programmes on the spread of HIV in IDUs has been lim-
ited in studies carried out in the US [29] and in Canada
[30] with the conclusion that whilst needle exchange pro-
grammes are crucial for sterile syringe provision, they
should be considered one component of a comprehensive
programme including counselling, support, and educa-
tion. Wright and Tompkins [31] in a systematic review of
the evidence for the effectiveness of primary prevention
interventions for Hepatitis C among injecting drug users
reported that needle exchange programmes reduced the
prevalence of Hepatitis C though prevalence remains
high. However, methadone maintenance treatment was
found to be only marginally effective at reducing HCV
incidence and limited evidence evaluating the effective-
ness of behavioural interventions in reducing its inci-
Table 4: Changes in risk behaviour and alcohol misuse
Drug and Alcohol Baseline Six-Month follow-up
EPC n = 37 SEC n = 41 EPC n = 36 SEC n = 41 Effect of
 Treatment
χ2 analysis N % N % N % N % p
IRQ – injected at all in last
six months
37.0 100.0 41.0 100.0 20 55.6 24 58.5 0.07 0.79
IRQ – Shared any IV
equipment at all in last
6 months
21.0 56.8 27.0 65.9 6 16.6 8 19.5 0.10 0.75
Used needle exchange in 
the last six months
21.0 56.8 23.0 56.1 16 44.4 17 41.5 0.07 0.79
AUDIT (score of 8 or more) 11.0 29.7 16.0 39.0 8 22.2 7 17.1 0.32 0.57
Table 5: Changes in situational confidence, hepatitis C knowledge and readiness to change measures
Measure Baseline Six-month Follow-up
EPC n = 37 SEC n = 41 EPC n = 36 SEC n = 41 Effect of 
Treatment
Effect of 
Time
ANCOVA Mean sd Mean sd Mean sd Mean sd F p F p
DICQ – Unpleasant emotions 49.27 30.1 54.51 30.06 56.86 28.8 62.85 31.56 0.38 0.54 14.44 0.00
DICQ – Physical discomfort score 56.76 27.2 61.9 28.26 64.11 24.09 66.27 30.85 0.01 0.92 10.07 0.00
DICQ – Pleasant emotions 74.16 25.3 79.17 21.67 77.44 24.62 78.51 25.73 0.03 0.87 15.38 0.00
DICQ – Testing personal control 57.76 30.7 60.44 31.51 64.53 28.76 63.1 32.42 0.05 0.82 11.54 0.00
DICQ – Urges and temptations 49.27 30.2 56.98 29.4 58.22 28.41 59.61 31.64 0.06 0.81 15.08 0.00
DICQ – Conflict with others 59.27 30.3 65.24 28.36 67.61 26.35 68.59 30.84 0.07 0.79 20.54 0.00
DICQ – Social pressure to use 49.43 32.9 52.68 34.48 48.5 35.9 56.54 34.49 0.92 0.34 20.63 0.00
DICQ – Pleasant times with others score 59.14 27.5 63.49 28.64 67.5 27.02 68.68 29.12 0.00 0.99 13.93 0.00
DICQ – Overall score 56.08 26.8 61.76 26.14 61.06 25.14 65.73 28.2 0.22 0.64 21.68 0.00
Hepatitis-C Knowledge Questionnaire 16.22 2.29 16.2 1.79 17.44 1.89 17.61 1.66 0.08 0.78 16.46 0.00
Readiness to change stage 2.54 0.73 2.54 0.78 2.58 0.73 2.56 0.78 0.00 0.99 0.57 0.45Harm Reduction Journal 2008, 5:25 http://www.harmreductionjournal.com/content/5/1/25
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dence. The review concluded that a robust response to the
global health problem of HCV would require the provi-
sion of new behavioural interventions in addition to nee-
dle exchange and methadone maintenance programmes.
Indeed one study [32] showed that in IDUs attending nee-
dle exchange schemes, brief intervention was effective in
reducing alcohol use and probably attendant risk factors
resulting in lower incidence of HCV in IDUs. Whilst the
design of the present study has not enabled the examina-
tion of the contribution of treatment, needle exchange
and HCV screening on the incidence of HCV, it is conceiv-
able that both the SEC and the EPC interventions, in addi-
tion to the provision of treatment, together with the
availability of needle exchange schemes for the present
cohort of IDUs, has contributed to the low incidence rate
of HCV in this population. Moreover, it is also conceiva-
ble that the testing regime instigated by the Research Team
itself encouraged a change in risk behaviour: pre-test
counselling in conjunction with the issues raised in the
baseline interview, and a degree of self-selection. The
impact of pre-test counselling alone is thus a potentially
important mechanism of change in risk behaviour worthy
of further investigation, and would indeed be a very
encouraging development if it could be proven to be effec-
tive. In conjunction with the DBS, which has been shown
to increase testing rates more than four-fold, the possibil-
ity of much greater testing taking place at primary care and
other community settings, may help to monitor infection
rates and help those who are not infected to remain so.
Enhanced Prevention Counselling
The EPC intervention described here is one of the first
such interventions developed specifically for the preven-
tion of HCV with injection drug users. A process evalua-
tion suggested that EPC facilitated a positive therapeutic
alliance compared with the SEC control intervention and
was perceived as beneficial by the IDUs in helping reduce
HCV-risks [33]. The intervention was deliberately
designed to be an enhanced counselling intervention as
opposed to a Brief Intervention (BI) of one session only.
A major difficulty, however, with the intervention was in
attendance for treatment sessions; the majority of partici-
pants who engaged only attended for one EPC session.
Thus in retrospect it appears that enhanced counselling is
unlikely to be more effective than a single session BI as
participants attend one session (at least in this study)
regardless of what is on offer. Participants attended as nor-
mal for standard key working and therefore one implica-
tion may be that only one session is offered and any
further work from this therapy programme might be bet-
ter placed within standard key working.
A comparison with a group given no information or
advice whatsoever is obviously not ethically possible and
so the question as to whether any intervention, however
brief, has any benefit (let alone knowing what the essen-
tial components of any intervention are) cannot be
answered from the current study. From our clinical and
field research experience, however, it seems likely that
there are elements common to both interventions in this
research that might be effective in helping prevent HCV
infection. As with the Tucker [27] study, it is possible that
the essential components of prevention in this clinical
population is the time spent with the health professional
and researcher, completion of the standardised question-
naires and particularly discussion of risk behaviours and
the heightened awareness of risk this produced. The EPC
may be made more fit for purpose by reducing the
number of sessions from 4 to one or 2 sessions the first of
which could be grafted on the post-HCV counselling ses-
sions: this would ensure its higher uptake by IDUs and
enable its evaluation. Moreover preventive behavioural
interventions should be informed by reference to IDUs
experience and views using qualitative methods such as
focus groups.
Methodological issues
The main problems encountered in the design, conduct
and delivery of this research were the lower than expected
levels of recruitment to the trial, and the low adherence to
EPC but not the SEC. Retention of participants once
recruited however was a lesser problem, as 65% of those
recruited were followed-up, and adherence to the infor-
mational one brief session intervention was not a prob-
lem, as more than 90% of those randomised to the SEC
informational intervention received it. The reasons for
these two main problems can be grouped under issues
relating to the participants' behaviour; issues relating to
the service environment from which participants were
recruited and issues relating to the trial design [6].
Lessons learnt
One of the main lessons learned in this project is that con-
ducting research in UK treatment settings presents chal-
lenges that are very different from those encountered in
US studies upon which research in addiction is often
modelled, as was the case in this project. RCTs in the US
are usually conducted against a background of higher
funding which facilitates pilot work, the formation of
larger research teams, and therapists who are dedicated to
the trial rather than relying on service staff trained in
delivering the experimental and control interventions.
Research in the US also benefits from a well-established
clinical research infrastructure, which aids the introduc-
tion of new interventions, increasing compliance from
staff and users. Indeed, the development and fostering of
a culture of research within the services involved in the
present trial was a task that had to be instigated. There is
also reason to believe that the clinical populations in the
US are different to those in the UK, with those engaged inHarm Reduction Journal 2008, 5:25 http://www.harmreductionjournal.com/content/5/1/25
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treatment being older, and more socially stable; this is of
consequence because it is important that service users are
well-engaged in standard drug treatment regimes before
introducing further demands such as structured counsel-
ling sessions. Another of the lessons learnt is the need for
piloting of the new intervention in an area of research that
involves the development of new interventions amongst a
difficult clinical population, with only limited guidance
available from other research.
One of the main policy implications for conducting trials
of psychological interventions within addiction health
care settings is for funding bodies to provide the necessary
resources to improve the quality and comprehensiveness
of treatment including the provision psychological inter-
ventions. This would provide the necessary infrastructure
and capacity for the development of innovative interven-
tions and thus offering opportunities for the evaluation of
their effectiveness and cost-effectiveness in pragmatic clin-
ical trials.
Conclusion
We were not able to prove the efficacy of EPC in compar-
ison with SEC in the prevention of hepatitis C in IDUs.
Notwithstanding the negative findings of this research, we
believe that the study has provided the benefits of devel-
oping and introducing specific behavioural primary pre-
ventive interventions (vide supra): the EPC and SEC
interventions (manuals available from the authors) [33]
and the DBS which hold promise and warrant further
investigation. Moreover the main lessons learnt were that
piloting of a new intervention is a crucial first step before
conducting pragmatic RCTs of psychological interven-
tions in the field of addiction; that an infrastructure and
culture for psychosocial interventions is needed to enable
applied research in the service environment, and research
funding is needed for enabling the recruitment of dedi-
cated trained therapists for the delivery of these interven-
tions.
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